Table 8 Disease association of mRNAs selected by categorical regression-based FE and BAHSIC

Cardiomyopathy, dilated (5.49×10⁻⁷, 1.80×10⁻¹⁰); Cardiomyopathies (1.5×10⁻⁴, 9.19×10⁻⁵); Cardiomyopathy, hypertrophic (5.6×10⁻³, 4.74×10⁻¹⁰); Heart defects, congenital (1.90×10⁻², —); Heart failure (—, 1.02×10⁻⁵); Cardiomyopathy, hypertrophic, familial (—, 1.02×10⁻⁵)

Cardiomyopathy, hypertrophic (—, 3.05×10⁻²)

Heart Defects, congenital (8.64×10⁻⁴, —); Cardiomegaly (1.46×10⁻³, —)

Heart defects, congenital (1.40×10⁻⁷, —); Heart septal defects (4.12×10⁻³, —); Hypertrophy, right ventricular (1.36×10⁻⁴, —); Cardiovascular abnormalities (1.49×10⁻³, —); Cardiomyopathy, dilated (8.14×10⁻³, —); Cardiomyopathies (9.27×10⁻³, —); Cardiomegaly (1.75×10⁻², 7.60×10⁻³)

Cardiomyopathies (3.87×10⁻³, —);

Cardiomegaly (7×10⁻²¹, 1.33×10⁻³); Cardiomyopathy, dilated (2.68⁻¹², 7.37⁻⁹); Cardiomyopathies (5.87×10⁻¹², 9.69 × 10⁻⁴); Heart Failure (6.50 × 10⁻¹², —); Cardiac Output, low (2.01 × 10⁻⁷, —); Arrhythmias, cardiac (8.85 ×10⁻⁷, —); Hypertrophy, left ventricular (3.03×10⁻⁶, 3.38×10⁻²); Myocardial reperfusion injury (2.33×10⁻⁵, —) Myocardial stunning (3.42×10⁻³, —); Atrial fibrillation (5.42×10⁻³, —); Myocardial infarction (6.11×10⁻³, —); Heart disease (2.38×10⁻², 7.00×10⁻⁴); Ventricular dysfunction, left (2.74×10⁻², 3.4×10⁻⁴); Cardiomyopathy, restrictive (—, 2.12×10⁻³); Myocardial ischemia (—, 2.91×10⁻³); Mitral valve insufficiency (—, 3.68×10⁻³); Cardiomyopathy, hypertrophic (—, 3.49×10⁻²)

(Already identified by CPCAFE)

Heart Defects, congenital (2.53×10⁻⁵⁵, 9.09×10⁻⁹); Cardiomegaly (1.11×10⁻²⁸, —); Cardiomyopathies (7,57×10⁻¹⁷, —); Hypertrophy, left ventricular (9.16×10⁻¹², 1.19×10⁻¹³); Cardiomyopathy, dilated (6.47×10⁻¹¹, 2.41×10⁻⁸); Heart disease (9,72×10⁻⁸, 1.11×10⁻⁴); Endocardial cushion defects (3.51×10⁻⁶, —); Heart septal defects (4.63×10⁻⁶, —); Cardiovascular abnormalities (6.34×10⁻⁵, —); Tachycardia, ectopic atrial (1.97×10⁻⁴, —); Arrhythmias, cardiac (4.35×10⁻⁴, —); Cardiomyopathy, hypertrophic, familial (4.90×10⁻³, —); Heart septal defects, ventricular (5.70×10⁻³, —); Hypertrophy, right ventricular (1.04×10⁻², —); Heart failure (1.04×10⁻², 5.07×10⁻²⁹); Cardiomyopathy, hypertrophic (2.20×10⁻², 4.40×10⁻²) Ventricular dysfunction, left (—, 3.04×10⁻¹⁰); Myocardial reperfusion injury (— 1.76×10⁻⁷); Cardiovascular disease (—, 4.21×10⁻⁶); Myocardial infarction (—, 9.73×10⁻⁶); Mitral valve insufficiency (—, 1.04×10⁻⁵); Heart valve disease (—, 3.27×10⁻⁵); Myocardial ischemia (—, 1.49×10⁻⁴); Ventricular dysfunction (—,.198×10⁻³); Cardiomyopathy, restrictive (—, 2.68×10⁻²); Ventricular dysfunction, right (—, 3.53×10⁻³)

Heart defects, congenital (6×10⁻³, —)

Heart defects, congenital (2.54×10⁻³⁸, —); Cardiomyopathy, dilated (6.55×10⁻⁹, 2.16×10⁻¹⁴); Heart septal defects (5.15×10⁻⁷, 6.80×10⁻⁴); Arrhythmias, cardiac (4.90×10⁻⁵, —); Cardiomyopathies (2.75×10⁻⁴, 1.23×10⁻²); Heart septal defects, atrial (1.33×10⁻³); Cardiovascular abnormalities (3.85×10⁻², —); Cardiomegaly (4.45×10⁻², 1.01×10⁻⁴); Cardiomyopathy, hypertrophic (—, 4.91×10⁻¹³); Cardiomyopathy, hypertrophic, familial (—, 1.97×10⁻⁶); Cardiomyopathy, restrictive (—, 5.87×10⁻⁴); Heart septal defects, atrial (—, 1.73×10⁻³); Hypertrophy, left ventricular (—, 1.09×10⁻²)

Heart defects, congenital (3.98×10⁻¹², 4.70×10⁻⁵); Cardiomegaly (2.52×10⁻⁶, 1.00×10⁻²); Cardiomyopathies (9.11×10⁻⁵, —); Heart septal defects (6.18×10⁻⁴, —); Cardiomyopathy, hypertrophic, familial (9.66×10⁻⁴, —); Cardiomyopathy, dilated (1.22×10⁻², 1.22×10⁻²); Heart failure (—, 3.04×10⁻⁴); Hypertrophy, left ventricular (—, 7.55×10⁻³)

(Already identified by CPCAFE)

(Already identified by CPCAFE)

(Already identified by CPCAFE)

(Already identified by CPCAFE)

(Already identified by CPCAFE)

Already identified by categorical regression based FE

Cardiomyopathy, hypertrophic (—, 2.46×10⁻²); Heart disease (—, 2.64×10⁻²); Cardiomyopathies (—, 3.10×10⁻²)

Myocardial reperfusion injury (—, 1.56×10⁻³)